Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.43, $0.12 better than the analyst estimate of $1.31. Revenue for the quarter came in at $4.97 billion versus the consensus estimate of $4.9 billion.

Teva Pharma sees FY2015 EPS of $5.15-$5.40, versus prior guidance of $5.05-$5.35 and the consensus of $5.26.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.